Free Trial
TSE:BHC

Bausch Health Companies Q3 2026 Earnings Results & Report

Bausch Health Companies logo
C$11.47 -0.94 (-7.57%)
As of 10/30/2026 04:00 PM Eastern

Bausch Health Companies reported Q3 2026 earnings on October 28, 2026. The company reported EPS of C$2.52, while revenue was C$4.19 billion.

Earnings Announcement Details

Quarter
Q3 2026
Report Date
Time
After Market Closes

Bausch Health Companies EPS Results

Actual EPS
C$2.52
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 8 quarters

Bausch Health Companies Revenue Results

Actual Revenue
C$4.19 billion
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Bausch Health Companies Q3 2026 Earnings FAQ

Bausch Health Companies (TSE:BHC) reported earnings of C$2.52 per share for Q3 2026. The report was announced on Wednesday, October 28, 2026.

Bausch Health Companies reported revenue of C$4.19 billion for Q3 2026.

Bausch Health Companies Earnings Headlines

Share Repurchase Program Approved by Bausch Health Companies (TSE:BHC)
What Elon Musk's Cybercab Reveal Could Mean for Investors
Jeff Brown, the analyst who flagged Bitcoin, Tesla, and Nvidia early, is tracking Elon Musk's next move. He points to a new AI project tied to Musk's Cybercab reveal. Brown says Musk has opened major investment windows before, with PayPal, Tesla, and SpaceX marking milestones in tech history. He believes a fourth may open by October 30.tc pixel
Bausch Health (BHC) Q3 2026 Earnings Call Transcript
See More Bausch Health Companies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bausch Health Companies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bausch Health Companies and other key companies, straight to your email.

About Bausch Health Companies

Bausch Health Companies (TSE:BHC) (NYSE:BHC)(TSX:BHC) is a global diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors.

View Bausch Health Companies Profile